Story perspectives

Insmed Halts Brensocatib Study, Shifts Focus to INS1148

12/18/2025

Summary

Story summary

Insmed Incorporated announced that its Phase 2b BiRCh study of brensocatib for chronic rhinosinusitis without nasal polyps failed to meet primary and secondary endpoints.
The 288-patient, 104-site trial showed brensocatib was well tolerated with no new safety concerns.
As a result, Insmed discontinued the CRSsNP program.
Insmed acquired INS1148, a monoclonal antibody for respiratory and inflammatory diseases, and will advance it in interstitial lung disease and asthma.

1 of 1

Story summary

Insmed Incorporated announced that its Phase 2b BiRCh study of brensocatib for chronic rhinosinusitis without nasal polyps failed to meet primary and secondary endpoints.
The 288-patient, 104-site trial showed brensocatib was well tolerated with no new safety concerns.
As a result, Insmed discontinued the CRSsNP program.
Insmed acquired INS1148, a monoclonal antibody for respiratory and inflammatory diseases, and will advance it in interstitial lung disease and asthma.